Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2022

Optimal treatment approach of stage IIIa: Oncogenic vs non-oncogenic driven

Q&A and discussion

Date

04 Dec 2022

Session

Optimal treatment approach of stage IIIa: Oncogenic vs non-oncogenic driven

Presenters

Hidehito Horinouchi

Authors

H. Horinouchi

Author affiliations

  • Department Of Thoracic Oncology, National Cancer Center - Tsukiji Campus, 104-0045 - Chuo-ku/JP

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Pathologist’s perspective

Presenter: The-Ying Chou

Session: Optimal treatment approach of stage IIIa: Oncogenic vs non-oncogenic driven

Resources:

Slides

Webcast

Surgeon’s perspective

Presenter: Tetsuya Mitsudomi

Session: Optimal treatment approach of stage IIIa: Oncogenic vs non-oncogenic driven

Resources:

Slides

Webcast

Radiation oncologist’s perspective

Presenter: Cécile Le Pechoux

Session: Optimal treatment approach of stage IIIa: Oncogenic vs non-oncogenic driven

Resources:

Slides

Webcast

Medical oncologist’s perspective

Presenter: Johan Vansteenkiste

Session: Optimal treatment approach of stage IIIa: Oncogenic vs non-oncogenic driven

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.